News

Back
09 Nov 2020

Wonderful Sky Financial Group Assists RemeGen Co., Ltd. (Stock Code: 9995.HK) with the Successful Listing on HKEx

RemeGen Co., Ltd. (Stock Code: 9995) was successfully listed and commenced trading on the Main Board of The Stock Exchange of Hong Kong Limited (“SEHK”) today.

 

RemeGen is a commercial-ready biopharmaceutical company committed to the discovery, development and commercialization of first-in-class and best-in-class biologics for the treatment of autoimmune, oncology and ophthalmic diseases with unmet medical needs in China and globally. The vision of the Company is to become a leading player in the global biopharmaceutical industry. Since their inception in 2008, RemeGen has been dedicated to the research and development of biologics with novel targets, innovative design and breakthrough potential to address global unmet clinical needs. Through more than ten years of meticulous efforts, RemeGen has built a fully-integrated, end-to-end therapeutics platform encompassing all the key biologic drug development functionalities, including discovery, pre-clinical pharmacology, process and quality development, clinical development, and manufacturing in compliance with global good manufacturing practice (GMP).

 

Leveraging their strong research and development (R&D) platforms, RemeGen has discovered and developed a robust pipeline of more than ten drug candidates. Among their drug candidates, five are in clinical development stage targeting 17 indications and more than five are in the investigational new drug (IND) application filing preparation stage. Two of their clinical-stage candidates, telitacicept (RC18) and disitamab vedotin (RC48), are in registrational trials targeting six indications in China and the U.S. The new drug application (NDA) of RemeGen for telitacicept in China for systemic lupus erythematosus (SLE) was accepted by the National Medical Products Administration (NMPA) in November 2019 and was granted priority review the following month. RemeGen expects to receive approval from the NMPA to market telitacicept in China for SLE in the fourth quarter of 2020.

 

As the only major integrated financial communications company in the world that is listed on the HKEx, Wonderful Sky will continue to provide a "one-stop” and ten-in-one prime financial public relations services, including financial public relations, investor relations, international roadshows, financial printing , corporate branding, ESG report, asset management, corporate doctor, Compulsory and Commercial Insurance and headhunting program. “Your Success is Our Inspiration” is the motto of Company's Group, by which we strive to become the select partner of listed companies for the long term by offering customized and professional services to Company's clients.